



**Press Release**

Thursday , April 22 , 2010

Strides Arcolab Limited,  
Strides House,  
Bannerghatta Road,  
Bangalore – 560076, India

BSE: 532531  
NSE: STAR

---

**STRIDES ARCOLAB ANNOUNCES US FDA TENTATIVE  
APPROVAL OF ADDITIONAL ADENOSINE INJECTION**

**APPROVAL MOMENTUM CONTINUES - TOTAL APPROVALS IN  
STERILE SPACE AT 23**

---


Strides Arcolab Limited (Strides) today announced that the U.S. Food and Drug administration had granted tentative approval of adenosine injection, USP, the generic equivalent of Astellas Pharmaceuticals' Adenoscan<sup>®</sup>, in 60 mg per 20 mL and 90 mg per 30 mL vials. IMS data indicates that the 2009 U.S. innovator market for these adenosine presentations approximated \$124 million. The product will be launched upon expiry of applicable innovator patents.

Upon approval, Adenosine will be launched under the partnership between Strides and Sagent Pharmaceuticals wherein Strides is developing and supplying more than 25 injectable products for the U.S. market which will be marketed by Sagent.

**About Strides Arcolab Limited:**

Strides Arcolab, listed on the Bombay Stock Exchange Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical company headquartered in Bangalore, India that develops and manufactures a wide range of IP-led niche pharmaceutical products with an emphasis on sterile injectables.

The company has 14 manufacturing facilities across 6 countries with marketing presence in more than 60 countries in developed and emerging markets. Manufacturing is ably supported by a 350-scientist strong global R&D Centre located in Bangalore. Additional information is available at the company's website at [www.stridesarco.com](http://www.stridesarco.com).



## About Sagent Pharmaceuticals, Inc.

Sagent Pharmaceuticals, founded in 2006, is a privately held specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectable products. Sagent has created a unique, global network of resources, comprised of rapid development capabilities, sophisticated manufacturing and innovative drug-delivery technologies, quickly yielding an extensive portfolio of pharmaceutical products that fulfills the evolving needs of patients. Sagent currently has more than 200 products in development.

To Discover Injectables Excellence™ and learn more about Sagent, please visit [www.SagentPharma.com](http://www.SagentPharma.com).

For further information, please contact:

Mr. Ravi Seth CEO – International Operations Ph: +91 80 6658 0121	Mr. Mahesh Nair, Corporate Voice/ Weber Shandwick Mobile : +91 98803 76648 Email: <a href="mailto:mareshn@corvoshandwick.co.in">mareshn@corvoshandwick.co.in</a>
Mr. N Kannan, Company Secretary (Investors) Tel : +91 80 6658 0751	Ms. Kasturi Wasmatkar, Corporate Voice/ Weber Shandwick Mobile: 99167 28393 Email: <a href="mailto:kasturi@corvoshandwick.co.in">kasturi@corvoshandwick.co.in</a>
Ms. Melissa Arulappan (Media) Tel: +91 98450 22389	

